Veeva Systems (VEEV) concentration risks

The company's concentration profile combines a geographic revenue tilt toward North America and a moderate customer-level dependency, both at disclosed sizes that do not individually reach the highest band. The geographic exposure is framed in the filing from the outside in: customers outside North America accounted for approximately 40% of total revenues, implying a high-share concentration in North America by residual, a structural reflection of where the life sciences software market is deepest and where the company has the longest commercial history. The structural character means this reflects the geography of pharmaceutical and biotech R&D and commercial activity rather than reliance on any single country or contract. The top 10 customers accounted for 28% of total revenues, a medium-share dependency by disclosed size. At that level the top-10 concentration is not extreme for an enterprise software business serving large pharmaceutical companies, but it does mean that renewal decisions, platform expansion, or contraction at the largest accounts carry noticeable revenue implications. The life sciences customer base tends to consolidate through M&A, which can create binary events where a merger combines two top-10 customers into one, reducing count and potentially renegotiating terms. Together the profile is well-balanced relative to software peers: a structural North America tilt reflects the center of the served market, and the top-10 customer dependency is moderate enough that no single-name departure would be decisive, though large pharma M&A remains a watch variable.

For the engine’s reasoning on VEEV’s current verdict — including which dimensions drove the score — see the per-dimension breakdown.

Concentration counts reflect items disclosed in each peer’s most recent 10-K; disclosed-size classification uses TrendMatrix’s internal 10-K extraction taxonomy.